HOW WE COMPARE

The honest comparison.

Exigyn against the legacy FP&A platforms biotech finance teams typically evaluate. No feature theater — just what each vendor actually ships in the base plan.

Capability
Exigyn
Biotech-native FP&A
Adaptive
Workday
Anaplan
Thoma Bravo
Jirav
SMB FP&A
NetSuite
Oracle
R&D Logic
Biotech FP&A
Biotech-native capabilities
Prebuilt biotech modules
Clinical budget, cash runway, headcount, R&D capex — live on day one
Clinical trial budget modeling
Per-site, per-visit accrual with enrollment kinetics and change orders
Cash runway with milestone overlays
Program-level spend gates tied to clinical readouts and data inflection points
Program-level P&L by asset
Spend by therapeutic program, not just by department
AI & integration
Excel add-in
Native Office add-in with a live, two-way link between your workbook and the platform
AI connector for Excel
AI agents — variance, BVA, runway — run against your workbook from the task pane
AI connector for PowerPoint
Board deck pages that refresh automatically from source data
MCP-native architecture
Your existing AI tools (Claude, ChatGPT, Cursor) can query your plan directly
Real-time what-if modeling
Change a driver, see the cash impact instantly — no batch recompute
Speed to value
Live in under 7 days
Preloaded sample company
Fictional clinical-stage biotech with trial budget and headcount plan — usable on day one
No implementation fees
Legacy vendors typically charge $50K–$500K in implementation services
Pricing published publicly
No sales call required to see module, suite, or platform pricing
No annual lock-in
Month-to-month or annual, your choice. Walk away any time.
Enterprise & compliance
Unlimited users (no per-seat fees)
Scenario modeling
Multi-entity consolidation
SSO & audit trails
SOC 2 Type II
21 CFR Part 11 support
For FDA-adjacent workflows requiring validated e-signatures and audit trails
Standard / included
Partial / add-on / custom build
Not offered
Based on publicly available information and typical vendor configurations as of April 2026. Competitor names are trademarks of their respective owners.